


In an aspect, there is provided a compound of the following formula:



wherein R¹, R² and R⁴ are each independently H or a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group;
- an amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;

- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group;

R^3 is a group selected from the following groups:

- a halogen;
- a linear or branched C_1 - C_6 alkyl group;
- a linear or branched C_1 - C_6 alkyl-aryl group;
- a linear or branched C_1 - C_6 halogenated alkyl group;
- a linear or branched primary secondary or tertiary C_1 - C_6 amine group;
- a amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C_3 - C_8 alkyl group;
- a linear or branched C_1 - C_6 alcohol group;
- a linear or branched C_1 - C_6 carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C_1 - C_6 carboxylic acid ester group;
- a linear or branched C_1 - C_6 amide group;
- a linear or branched C_1 - C_7 amino acyl group;
- a linear or branched C_1 - C_7 alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group;

R^6 is H or a group selected from the following groups:

- a halogen;

- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary secondary or tertiary C₁-C₆ amine group;
- a amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group;

X is independently selected from N, or O;

each of R⁷¹, or R⁷² is independently H or a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary secondary or tertiary C₁-C₆ amine group;
- a amino-aryl group;
- a cyclic amine or amido group;
- a cyclic C₃-C₈ alkyl group;

- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group including an aromatic heterocyclic group;

R⁷³ is a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary secondary or tertiary C₁-C₆ amine group;
- a amino-aryl group;
- a cyclic amine or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;

- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group including an aromatic heterocyclic group;

or two R^{72} groups may together form a carbonyl group;


and R^{73} is absent when its X atom is O or S; and wherein

an R^{72} and R^{73} may together form a saturated or unsaturated aliphatic or aromatic homocyclic or unsaturated heterocyclic ring.

In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a carrier.

In another aspect, there is provided the pharmaceutical composition as defined herein, for use in treating a cancer, an inflammatory condition, an autoimmune condition, a neurological condition, a proliferative disorder and/or a metabolic condition in a patient.

In another aspect, there is provided a compound, wherein the compound is of the following formula:



wherein in (I) the substituents are selected from one of the following groups (i)-(iv):

(i) R^3 is selected from a saturated carbocyclic ring having from 3 to 7 ring carbons; and an aromatic ring having from 3 to 7 ring carbons provided that it is not a 4-methylphenyl group;

R^6 is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms; X is N;

R^{73} is a $-(CO)-R^{75}$ group;

wherein R^1 , R^2 , and R^4 are independently selected from H and a group selected from the following groups

- a halogen;
- a linear or branched C_1-C_6 alkyl group;
- a linear or branched C_1-C_6 alkyl-aryl group;
- a linear or branched C_1-C_6 halogenated alkyl group;
- a linear or branched primary, secondary or tertiary C_1-C_6 amine group;
- an amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C_3-C_8 alkyl group;
- a linear or branched C_1-C_6 alcohol group;
- a linear or branched C_1-C_6 carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C_1-C_6 carboxylic acid ester group;
- a linear or branched C_1-C_6 amide group;
- a linear or branched C_1-C_7 amino acyl group;
- a linear or branched C_1-C_7 alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;

- a cyclic aminosulphonyl- group; and
- a saturated or unsaturated heterocyclic group; and

wherein each of R^{71} , R^{72} and R^{75} is independently H or a group selected from the following groups:

- a halogen;
- a linear or branched C_1 - C_6 alkyl group;
- a linear or branched C_1 - C_6 alkyl-aryl group;
- a linear or branched C_1 - C_6 halogenated alkyl group;
- a linear or branched primary, secondary or tertiary C_1 - C_6 amine group;
- an amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C_3 - C_8 alkyl group;
- a linear or branched C_1 - C_6 alcohol group;
- a linear or branched acyl group;
- a linear or branched C_1 - C_6 carboxylic acid ester group;
- a linear or branched C_1 - C_6 amide group;
- a linear or branched C_1 - C_7 amino acyl group;
- a linear or branched C_1 - C_7 alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group; and
- a saturated or unsaturated heterocyclic group;

(ii) R^3 is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms;

R^6 is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms;

X is independently selected from N, O and S; wherein R^{73} is absent when its X is O or S; and

wherein R^1 , R^2 , R^4 , R^{71} , R^{72} and R^{73} are as defined in section (i) above;

(iii) R^3 is a $-Z(R^{33})_2$ group in which Z is C ;

R^{33} is selected from a linear or branched alkyl group optionally forming a non-aromatic carbocyclic or heterocyclic ring with another R^{33} , a substituted sulphonyl group, and an acyl group; provided that the $-Z(R^{33})_2$ group is not $-NH_2$ or an amide bonded to the ring via a C atom;

R^6 is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms; X is N; and wherein R^{73} is a $-(CO)-R^{75}$ group; and


wherein R^1 , R^2 , R^4 , R^{71} , R^{72} and R^{75} are as defined under section (i) above;

(iv) R^6 is a saturated homocyclic or heterocyclic group having from 3-7 ring atoms in which each ring atom is selected from C, N, O or S, provided that R^6 is not adamantyl;


X is independently selected from N, O and S; wherein R^{73} is absent when its X is O or S; and

wherein R^1 , R^2 , R^3 , R^4 , R^{71} , R^{72} and R^{73} are as defined under section (i) above.


In another aspect, there is provided a compound, wherein the compound is selected from the group consisting of:




72















74















76




78







12k




106




108




110




112




115




117




119




107




109




111




114













116




118




120







134




136




137




138




139




140




141




142




143




144




145




146




147




148




149




150




151




152




153




154




155




156




157




158




160




162




164




166




159




161




163




165




169




170




171




172




173




174




175




176










177




178




179







190




191




192




193




194




195




196




197




199




200




201




202




203




204




205




206




207




210




211




212




213




214




215




218




219




220




221




223




226




229




222




225




227




230




231




232




233




234




235




236




237




238




239




240




241




242




243




244




245




246




247




248




249




251




257




259




262




250




252




258




260




263




264




266




270




275




277




278




279




280




281




282




283




284




285




286




287




289




290




291




292




293




294




295




298




299




300











301




303




304







315




316




317




318




319




320




324




325




326




327




328




329




332




333




334




335




336




337




338




339




341




342




343




345




346




350




351




352




353




354




355




356




357




359




360




361




362




363




364




365




367




368




369




370




371




372




373




374




375




376








377



378



379




In another aspect, there is provided a compound as defined herein for use in therapy.

In another aspect, there is provided use of a compound as defined herein in the manufacture of a medicament for the treatment of cancer, an inflammatory condition, an autoimmune condition, a neurological condition, a proliferative disorder and/or a metabolic condition.

In the context of the present disclosure, a compound is considered to be a SLC2A Class I transporter inhibitor if it is capable of reducing transport of a species (such as glucose) across an SLC2A Class I transporter receptor (such as GLUT1, GLUT2, GLUT3, GLUT4 and/or

CLAIMS:

1. A compound of the following formula:



wherein R¹, R² and R⁴ are each independently H or a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group;
- an amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C₃-C₈ alkyl group;

- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group;

R³ is a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;

- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary secondary or tertiary C₁-C₆ amine group;
- a amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group;

R⁶ is H or a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary secondary or tertiary C₁-C₆ amine group;
- a amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;

- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group;

X is independently selected from N, or O;

each of R⁷¹, or R⁷² is independently H or a group selected from the following groups:

- a halogen;
- a linear or branched C₁-C₆ alkyl group;
- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary secondary or tertiary C₁-C₆ amine group;
- a amino-aryl group;
- a cyclic amine or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched C₁-C₆ carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;

- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group including an aromatic heterocyclic group;

R^{73} is a group selected from the following groups:

- a halogen;
- a linear or branched C_1 - C_6 alkyl group;
- a linear or branched C_1 - C_6 alkyl-aryl group;
- a linear or branched C_1 - C_6 halogenated alkyl group;
- a linear or branched primary secondary or tertiary C_1 - C_6 amine group;
- a amino-aryl group;
- a cyclic amine or amido group;
- a cyclic C_3 - C_8 alkyl group;
- a linear or branched C_1 - C_6 alcohol group;
- a linear or branched C_1 - C_6 carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C_1 - C_6 carboxylic acid ester group;
- a linear or branched C_1 - C_6 amide group;
- a linear or branched C_1 - C_7 amino acyl group;
- a linear or branched C_1 - C_7 alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group;
- an aromatic group; and
- a saturated or unsaturated heterocyclic group including an aromatic heterocyclic group;

or two R^{72} groups may together form a carbonyl group;
and R^{73} is absent when its X atom is O or S; and wherein

an R^{72} and R^{73} may together form a saturated or unsaturated aliphatic or aromatic homocyclic or unsaturated heterocyclic ring.

2. A compound according to claim 1, wherein R^3 is a group selected from the following groups:

- a halogen;

- a linear or branched C_1 - C_6 alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl; preferably a C_3 - C_6 alkyl group (such as propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl);

- a linear or branched C_1 - C_6 alkyl-aryl group selected from $-\text{CH}_2\text{Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{F-Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{Cl-Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{Br-Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{I-Ph}$, $-\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$;

- a linear or branched C_1 - C_6 halogenated alkyl group selected from $-\text{CH}_2\text{F}$, $-\text{CH}_2\text{Cl}$, $-\text{CH}_2\text{Br}$, $-\text{CH}_2\text{I}$, $-\text{CF}_3$, $-\text{CCl}_3$, $-\text{CBr}_3$, $-\text{Cl}_3$, $-\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CCl}_3$, $-\text{CH}_2\text{CB}$ ₃, and $-\text{CH}_2\text{Cl}_3$;

- a linear or branched primary, secondary or tertiary C_1 - C_6 amine group selected from $-\text{NH}_2$, $-\text{NMeH}$, $-\text{NMe}_2$, $-\text{NEtH}$, $-\text{NEtMe}$, $-\text{NEt}_2$, $-\text{NPrH}$, $-\text{NPrMe}$, $-\text{NPrEt}$, $-\text{NPr}_2$, $-\text{NBuH}$, $-\text{NBuMe}$, $-\text{NBuEt}$, $-\text{CH}_2\text{-NH}_2$, $-\text{CH}_2\text{-NMeH}$, $-\text{CH}_2\text{-NMe}_2$, $-\text{CH}_2\text{-NEtH}$, $-\text{CH}_2\text{-NEtMe}$, $-\text{CH}_2\text{-NEt}_2$, $-\text{CH}_2\text{-NPrH}$, $-\text{CH}_2\text{-NPrMe}$, and $-\text{CH}_2\text{-NPrEt}$;

- an amino-aryl group selected from $-\text{NH-Ph}$, $-\text{NH-(2,3 or 4)F-Ph}$, $-\text{NH-(2,3 or 4)Cl-Ph}$, $-\text{NH-(2,3 or 4)Br-Ph}$, $-\text{NH-(2,3 or 4)I-Ph}$, $-\text{NH-(2,3 or 4)Me-Ph}$, $-\text{NH-(2,3 or 4)Et-Ph}$, $-\text{NH-(2,3 or 4)Pr-Ph}$, $-\text{NH-(2,3 or 4)Bu-Ph}$, $-\text{NH-(2,3 or 4)OMe-Ph}$, $-\text{NH-(2,3 or 4)OEt-Ph}$, $-\text{NH-(2,3 or 4)OPr-Ph}$, $-\text{NH-(2,3 or 4)OBu-Ph}$, $-\text{NH-2,(3,4,5 or 6)F}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Cl}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Br}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)I}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Me}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Et}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Pr}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Bu}_2\text{-Ph}$;

- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C₃-C₈ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
- a linear or branched C₁-C₆ alcohol group selected from -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂CH₂OH, and -CH₂CH₂CH₂CH₂CH₂CH₂OH;
- a linear or branched C₁-C₆ carboxylic acid group selected from -COOH, -CH₂COOH, -CH₂CH₂COOH, -CH₂CH₂CH₂COOH, -CH₂CH₂CH₂CH₂COOH, and -CH₂CH₂CH₂CH₂CH₂COOH;
- a linear or branched acyl group selected from -(CO)Me, -(CO)Et, -(CO)Pr, -(CO)iPr, -(CO)nBu, -(CO)iBu, -(CO)tBu, -(CO)Ph, -(CO)CH₂Ph, -(CO)CH₂OH, -(CO)CH₂OCH₃, -(CO)CH₂NH₂, -(CO)CH₂NHMe, -(CO)CH₂NMe₂, -(CO)-cyclopropyl, -(CO)-1,3-epoxypropan-2-yl, -(CO)NH₂, -(CO)NHMe, -(CO)NMe₂, -(CO)NH₂Et, -(CO)NEt₂, -(CO)-pyrrolidine-N-yl, -(CO)-morpholine-N-yl, -(CO)-piperazine-N-yl, -(CO)-N-methyl-piperazine-N-yl, -(CO)NHCH₂CH₂OH, -(CO)NHCH₂CH₂OMe, -(CO)NHCH₂CH₂NH₂, -(CO)NHCH₂CH₂NHMe, and -(CO)NHCH₂CH₂NMe₂;
- a linear or branched C₁-C₆ carboxylic acid ester group selected from -COOMe, -COOEt, -COOPr, -COO-i-Pr, -COO-n-Bu, -COO-i-Bu, -COO-t-Bu, -CH₂COOMe, -CH₂CH₂COOMe, -CH₂CH₂CH₂COOMe, and -CH₂CH₂CH₂CH₂COOMe;
- a linear or branched C₁-C₆ amide group selected from -CO-NH₂, -CO-NMeH, -CO-NMe₂, -CO-NEtH, -CO-NEtMe, -CO-NEt₂, -CO-NPrH, -CO-NPrMe, and -CO-NPrEt;

- a linear or branched C₁-C₇ amino acyl group selected from -NH-CO-Me, -NH-CO-Et, -NH-CO-Pr, -NH-CO-Bu, -NH-CO-pentyl, -NH-CO-hexyl, -NH-CO-Ph, -NMe-CO-Me, -NMe-CO-Et, -NMe-CO-Pr, -NMe-CO-Bu, -NMe-CO-pentyl, -NMe-CO-hexyl, -NMe-CO-Ph;
- a linear or branched C₁-C₇ alkoxy or aryloxy group selected from -OMe, -OEt, -OPr, -O-i-Pr, -O-n-Bu, -O-i-Bu, -O-t-Bu, -O-pentyl, -O-hexyl, -OCH₂F, -OCHF₂, -OCF₃, -OCH₂Cl, -OCHCl₂, -OCCl₃, -O-Ph, -O-CH₂-Ph, -O-CH₂-(2,3 or 4)-F-Ph, -O-CH₂-(2,3 or 4)-Cl-Ph, -CH₂OMe, -CH₂OEt, -CH₂OPr, -CH₂OBu, -CH₂CH₂OMe, -CH₂CH₂CH₂OMe, -CH₂CH₂CH₂CH₂OMe, and -CH₂CH₂CH₂CH₂CH₂OMe;
- a linear or branched aminoalkoxy group selected from -OCH₂NH₂, -OCH₂NHMe, -OCH₂NMe₂, -OCH₂NHEt, -OCH₂NEt₂, -OCH₂CH₂NH₂, -OCH₂CH₂NHMe, -OCH₂CH₂NMe₂, -OCH₂CH₂NHEt, and -OCH₂CH₂NEt₂;
- a sulphonyl group selected from -SO₂Me, -SO₂Et, -SO₂Pr, -SO₂iPr, -SO₂Ph, -SO₂-(2,3 or 4)-F-Ph, -SO₂-cyclopropyl, -SO₂CH₂CH₂OCH₃;
- a sulphonylamino group selected from -SO₂NH₂, -SO₂NHMe, -SO₂NMe₂, -SO₂NHEt, -SO₂NEt₂, -SO₂-pyrrolidine-N-yl, -SO₂-morpholine-N-yl, -SO₂NHCH₂OMe, and -SO₂NHCH₂CH₂OMe;
- an aminosulphonyl group selected from -NHSO₂Me, -NHSO₂Et, -NHSO₂Pr, -NHSO₂iPr, -NHSO₂Ph, -NHSO₂-(2,3 or 4)-F-Ph, -NHSO₂-cyclopropyl, -NHSO₂CH₂CH₂OCH₃;
- a cyclic aminosulphonyl- group selected from -N(SO₂)(CH₂)₃ and -N(SO₂)(CH₂)₄;
- an aromatic group selected from Ph-, 2-F-Ph-, 3-F-Ph-, 4-F-Ph-, 2-Cl-Ph-, 3-Cl-Ph-, 4-Cl-Ph-, 2-Br-Ph-, 3-Br-Ph-, 4-Br-Ph-, 2-I-Ph-, 3-I-Ph-, 4-I-Ph-, 2,(3,4,5 or 6)-F₂-Ph-, 2,(3,4,5 or 6)-Cl₂-Ph-, 2,(3,4,5 or 6)-Br₂-Ph-, 2,(3,4,5 or 6)-I₂-Ph-, 2,(3,4,5 or 6)-Me₂-Ph-, 2,(3,4,5 or 6)-Et₂-Ph-, 2,(3,4,5 or 6)-Pr₂-Ph-, 2,(3,4,5 or 6)-Bu₂-Ph-, 2,(3,4,5 or 6)-(CN)₂-Ph-, 2,(3,4,5 or 6)-(NO₂)₂-Ph-, 2,(3,4,5 or 6)-(NH₂)₂-Ph-, 2,(3,4,5 or 6)-(MeO)₂-Ph-, 2,(3,4,5 or 6)-(CF₃)₂-Ph-,

3,(4 or 5)-F₂-Ph-, 3,(4 or 5)-Cl₂-Ph-, 3,(4 or 5)-Br₂-Ph-, 3,(4 or 5)-I₂-Ph-, 3,(4 or 5)-Me₂-Ph-, 3,(4 or 5)-Et₂-Ph-, 3,(4 or 5)-Pr₂-Ph-, 3,(4 or 5)-Bu₂-Ph-, 3,(4 or 5)-(CN)₂-Ph-, 3,(4 or 5)-(NO₂)₂-Ph-, 3,(4 or 5)-(NH₂)₂-Ph-, 3,(4 or 5)-(MeO)₂-Ph-, 3,(4 or 5)-(CF₃)₂-Ph-, 2-Me-Ph-, 3-Me-Ph-, 4-Me-Ph-, 2-Et-Ph-, 3-Et-Ph-, 4-Et-Ph-, 2-Pr-Ph-, 3-Pr-Ph-, 4-Pr-Ph-, 2-Bu-Ph-, 3-Bu-Ph-, 4-Bu-Ph-, 2-(CN)-Ph-, 3-(CN)-Ph-, 4-(CN)-Ph-, 2-(NO₂)-Ph-, 3-(NO₂)-Ph-, 4-(NO₂)-Ph-, 2-(NH₂)-Ph-, 3-(NH₂)-Ph-, 4-(NH₂)-Ph-, 2-MeO-Ph-, 3-MeO-Ph-, 4-MeO-Ph-, 2-(NH₂-CO)-Ph-, 3-(NH₂-CO)-Ph-, 4-(NH₂-CO)-Ph-, 2-CF₃-Ph-, 3-CF₃-Ph-, 4-CF₃-Ph-, 2- CF₃O-Ph-, 3- CF₃O-Ph-, and 4- CF₃O-Ph-; and

- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1-yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl.

3. A compound according to claim 1 or 2, wherein R⁶ is H or a group selected from the following groups:

- a halogen selected from F, Cl, Br and I;

- a linear or branched C₁-C₆ alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl;

- a linear or branched C₁-C₆ alkyl-aryl group selected from -CH₂Ph, -CH₂(2,3 or 4)F-Ph, -CH₂(2,3 or 4)Cl-Ph, -CH₂(2,3 or 4)Br-Ph, -CH₂(2,3 or 4)I-Ph, -CH₂CH₂Ph, -CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂CH₂Ph, and -CH₂CH₂CH₂CH₂CH₂CH₂Ph;

- a linear or branched C₁-C₆ halogenated alkyl group selected from -CH₂F, -CH₂Cl, -CH₂Br, -CH₂I, -CF₃, -CCl₃, -CBr₃, -Cl₃, -CH₂CF₃, -CH₂CCl₃, -CH₂CBr₃, and -CH₂Cl₃;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group selected from -NH₂, -NMeH, -NMe₂, -NEtH, -NEtMe, -NEt₂, -NPrH, -NPrMe, -NPrEt, -NPr₂, -NBuH, -NBuMe, -NBuEt, -CH₂-NH₂, -CH₂-NMeH, -CH₂-NMe₂, -CH₂-NEtH, -CH₂-NEtMe, -CH₂-NEt₂, -CH₂-NPrH, -CH₂-NPrMe, and -CH₂-NPrEt;
- an amino-aryl group selected from -NH-Ph, -NH-(2,3 or 4)F-Ph, -NH-(2,3 or 4)Cl-Ph, -NH-(2,3 or 4)Br-Ph, -NH-(2,3 or 4)I-Ph, -NH-(2,3 or 4)Me-Ph, -NH-(2,3 or 4)Et-Ph, -NH-(2,3 or 4)Pr-Ph, -NH-(2,3 or 4)Bu-Ph, -NH-(2,3 or 4)OMe-Ph, -NH-(2,3 or 4)OEt-Ph, -NH-(2,3 or 4)OPr-Ph, -NH-(2,3 or 4)OBu-Ph, -NH-2,(3,4,5 or 6)F₂-Ph, -NH-2,(3,4,5 or 6)Cl₂-Ph, -NH-2,(3,4,5 or 6)Br₂-Ph, -NH-2,(3,4,5 or 6)I₂-Ph, -NH-2,(3,4,5 or 6)Me₂-Ph, -NH-2,(3,4,5 or 6)Et₂-Ph, -NH-2,(3,4,5 or 6)Pr₂-Ph, -NH-2,(3,4,5 or 6)Bu₂-Ph;
- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C₃-C₈ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
- a linear or branched C₁-C₆ alcohol group selected from -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂CH₂OH, and -CH₂CH₂CH₂CH₂CH₂CH₂OH;
- a linear or branched C₁-C₆ carboxylic acid group selected from -COOH, -CH₂COOH, -CH₂CH₂COOH, -CH₂CH₂CH₂COOH, -CH₂CH₂CH₂CH₂COOH, and -CH₂CH₂CH₂CH₂CH₂COOH;

- a linear or branched acyl group selected from $-(\text{CO})\text{Me}$, $-(\text{CO})\text{Et}$, $-(\text{CO})\text{Pr}$, $-(\text{CO})\text{iPr}$, $-(\text{CO})\text{nBu}$, $-(\text{CO})\text{iBu}$, $-(\text{CO})\text{tBu}$, $-(\text{CO})\text{Ph}$, $-(\text{CO})\text{CH}_2\text{Ph}$, $-(\text{CO})\text{CH}_2\text{OH}$, $-(\text{CO})\text{CH}_2\text{OCH}_3$, $-(\text{CO})\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{CH}_2\text{NHMe}$, $-(\text{CO})\text{CH}_2\text{NMe}_2$, $-(\text{CO})\text{-cyclopropyl}$, $-(\text{CO})\text{-1,3-epoxypropan-2-yl}$, $-(\text{CO})\text{NH}_2$, $-(\text{CO})\text{NHMe}$, $-(\text{CO})\text{NMe}_2$, $-(\text{CO})\text{NHEt}$, $-(\text{CO})\text{NEt}_2$, $-(\text{CO})\text{-pyrrolidine-N-yl}$, $-(\text{CO})\text{-morpholine-N-yl}$, $-(\text{CO})\text{-piperazine-N-yl}$, $-(\text{CO})\text{-N-methyl-piperazine-N-yl}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OH}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OMe}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NHMe}$, and $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NMe}_2$;

- a linear or branched $\text{C}_1\text{-C}_6$ carboxylic acid ester group selected from $-\text{COOMe}$, $-\text{COOEt}$, $-\text{COOPr}$, $-\text{COO-i-Pr}$, $-\text{COO-n-Bu}$, $-\text{COO-i-Bu}$, $-\text{COO-t-Bu}$, $-\text{CH}_2\text{COOMe}$, $-\text{CH}_2\text{CH}_2\text{COOMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{COOMe}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{COOMe}$;

- a linear or branched $\text{C}_1\text{-C}_6$ amide group selected from $-\text{CO-NH}_2$, $-\text{CO-NMeH}$, $-\text{CO-NMe}_2$, $-\text{CO-NEtH}$, $-\text{CO-NEtMe}$, $-\text{CO-NEt}_2$, $-\text{CO-NPrH}$, $-\text{CO-NPrMe}$, and $-\text{CO-NPrEt}$;

- a linear or branched $\text{C}_1\text{-C}_7$ amino carbonyl group selected from $-\text{NH-CO-Me}$, $-\text{NH-CO-Et}$, $-\text{NH-CO-Pr}$, $-\text{NH-CO-Bu}$, $-\text{NH-CO-pentyl}$, $-\text{NH-CO-hexyl}$, $-\text{NH-CO-Ph}$, $-\text{NMe-CO-Me}$, $-\text{NMe-CO-Et}$, $-\text{NMe-CO-Pr}$, $-\text{NMe-CO-Bu}$, $-\text{NMe-CO-pentyl}$, $-\text{NMe-CO-hexyl}$, $-\text{NMe-CO-Ph}$;


- a linear or branched $\text{C}_1\text{-C}_7$ alkoxy or aryloxy group selected from $-\text{OMe}$, $-\text{OEt}$, $-\text{OPr}$, $-\text{O-i-Pr}$, $-\text{O-n-Bu}$, $-\text{O-i-Bu}$, $-\text{O-t-Bu}$, $-\text{O-pentyl}$, $-\text{O-hexyl}$, $-\text{OCH}_2\text{F}$, $-\text{OCHF}_2$, $-\text{OCF}_3$, $-\text{OCH}_2\text{Cl}$, $-\text{OCHCl}_2$, $-\text{OCCl}_3$, $-\text{O-Ph}$, $-\text{O-CH}_2\text{-Ph}$, $-\text{O-CH}_2\text{-(2,3 or 4)-F-Ph}$, $-\text{O-CH}_2\text{-(2,3 or 4)-Cl-Ph}$, $-\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{OEt}$, $-\text{CH}_2\text{OPr}$, $-\text{CH}_2\text{OBu}$, $-\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$;

- a linear or branched aminoalkoxy group selected from $-\text{OCH}_2\text{NH}_2$, $-\text{OCH}_2\text{NHMe}$, $-\text{OCH}_2\text{NMe}_2$, $-\text{OCH}_2\text{NHEt}$, $-\text{OCH}_2\text{NEt}_2$, $-\text{OCH}_2\text{CH}_2\text{NH}_2$, $-\text{OCH}_2\text{CH}_2\text{NHMe}$, $-\text{OCH}_2\text{CH}_2\text{NMe}_2$, $-\text{OCH}_2\text{CH}_2\text{NHEt}$, and $-\text{OCH}_2\text{CH}_2\text{NEt}_2$;


- a sulphonyl group selected from -SO₂Me, -SO₂Et, -SO₂Pr, -SO₂iPr, -SO₂Ph, -SO₂-(2,3 or 4)-F-Ph, -SO₂-cyclopropyl, -SO₂CH₂CH₂OCH₃;
- a sulphonylamino group selected from -SO₂NH₂, -SO₂NHMe, -SO₂NMe₂, -SO₂NHEt, -SO₂NEt₂, -SO₂-pyrrolidine-N-yl, -SO₂-morpholine-N-yl, -SO₂NHCH₂OMe, and -SO₂NHCH₂CH₂OMe;
- an aminosulphonyl group selected from -NHSO₂Me, -NHSO₂Et, -NHSO₂Pr, -NHSO₂iPr, -NHSO₂Ph, -NHSO₂-(2,3 or 4)-F-Ph, -NHSO₂-cyclopropyl, -NHSO₂CH₂CH₂OCH₃;
- a cyclic aminosulphonyl- group selected from -N(SO₂)(CH₂)₃ and -N(SO₂)(CH₂)₄;
- an aromatic group selected from Ph-, 2-F-Ph-, 3-F-Ph-, 4-F-Ph-, 2-Cl-Ph-, 3-Cl-Ph-, 4-Cl-Ph-, 2-Br-Ph-, 3-Br-Ph-, 4-Br-Ph-, 2-I-Ph-, 3-I-Ph-, 4-I-Ph-, 2,(3,4,5 or 6)-F₂-Ph-, 2,(3,4,5 or 6)-Cl₂-Ph-, 2,(3,4,5 or 6)-Br₂-Ph-, 2,(3,4,5 or 6)-I₂-Ph-, 2,(3,4,5 or 6)-Me₂-Ph-, 2,(3,4,5 or 6)-Et₂-Ph-, 2,(3,4,5 or 6)-Pr₂-Ph-, 2,(3,4,5 or 6)-Bu₂-Ph-, 2,(3,4,5 or 6)-(CN)₂-Ph-, 2,(3,4,5 or 6)-(NO₂)₂-Ph-, 2,(3,4,5 or 6)-(NH₂)₂-Ph-, 2,(3,4,5 or 6)-(MeO)₂-Ph-, 2,(3,4,5 or 6)-(CF₃)₂-Ph-, 3,(4 or 5)-F₂-Ph-, 3,(4 or 5)-Cl₂-Ph-, 3,(4 or 5)-Br₂-Ph-, 3,(4 or 5)-I₂-Ph-, 3,(4 or 5)-Me₂-Ph-, 3,(4 or 5)-Et₂-Ph-, 3,(4 or 5)-Pr₂-Ph-, 3,(4 or 5)-Bu₂-Ph-, 3,(4 or 5)-(CN)₂-Ph-, 3,(4 or 5)-(NO₂)₂-Ph-, 3,(4 or 5)-(NH₂)₂-Ph-, 3,(4 or 5)-(MeO)₂-Ph-, 3,(4 or 5)-(CF₃)₂-Ph-, 2-Me-Ph-, 3-Me-Ph-, 4-Me-Ph-, 2-Et-Ph-, 3-Et-Ph-, 4-Et-Ph-, 2-Pr-Ph-, 3-Pr-Ph-, 4-Pr-Ph-, 2-Bu-Ph-, 3-Bu-Ph-, 4-Bu-Ph-, 2-(CN)-Ph-, 3-(CN)-Ph-, 4-(CN)-Ph-, 2-(NO₂)-Ph-, 3-(NO₂)-Ph-, 4-(NO₂)-Ph-, 2-(NH₂)-Ph-, 3-(NH₂)-Ph-, 4-(NH₂)-Ph-, 2-MeO-Ph-, 3-MeO-Ph-, 4-MeO-Ph-, 2-(NH₂-CO)-Ph-, 3-(NH₂-CO)-Ph-, 4-(NH₂-CO)-Ph-, 2-CF₃-Ph-, 3-CF₃-Ph-, 4-CF₃-Ph-, 2- CF₃O-Ph-, 3- CF₃O-Ph-, and 4- CF₃O-Ph-; and
- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1-yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-

yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl.


4. A compound according to any one of the preceding claims, wherein the group:




is selected from the following groups:



and also from a group having the following structure:




where the ring fused to the piperazine ring is a 5- or 6-membered ring optionally having 1 or more further heteroatoms in the ring selected from N and O and optionally having one or more substituents, preferably wherein this group is selected from the following:
















wherein R^{792} , R^{793} and R^{794} are selected from the following:


- R^{792} is selected from Me, Et, Pr, iPr, cyPr, cyBu, $-(CO)-Me$, $-(CO)-Et$, $-(CO)-Pr$, $-(CO)iPr$, $-SO_2Me$, and SO_2Et ;
- R^{793} is selected from Me, Et, Pr, iPr, cyPr, cyBu, $-(CO)-Me$, $-(CO)Et$, $-(CO)Pr$, and $-(CO)iPr$;
- R^{794} is selected from H, Me, Et, Pr, iPr, cyPr, cyBu; an unsubstituted, 2-,3- or 4-monosubstituted, and a 2,4 or 3,4-disubstituted phenyl group selected from 2-F-Ph, 2-Cl-Ph,

2-CN-Ph, 2-OMe-Ph, 3-F-Ph, 3-Cl-Ph, 3-CN-Ph, 3-OMe-Ph, 4-F-Ph, 4-Cl-Ph, 4-CN-Ph, 4-OMe-Ph, 2,4-F₂-Ph, 2,4-Cl₂-Ph, 2,4-(CN)₂-Ph, 2,4-(OMe)₂-Ph, 3,4-F₂-Ph, 3,4-Cl₂-Ph, 3,4-(CN)₂-Ph, and 3,4-(OMe)₂-Ph; -NH₂, -NHMe, and -NMe₂; -OH, -OMe, -OEt, -OPr, -OiPr, -OⁿBu, and -O^tBu; -CH₂OH, -CHMeOH, -C(Me)₂OH, -CH₂OMe, -CHMeOMe, -C(Me)₂OMe, -CH₂OEt, -CHMeOEt, and -C(Me)₂OEt; and a heterocyclic ring group having from 4-7 ring atoms with at least one heteroatom selected from N, O, and S, which ring group may be saturated or unsaturated and wherein the heterocyclic ring group is selected from the following groups:









5. A compound according to any one of the preceding claims, wherein R^1 , R^2 and R^4 are each independently H or a group selected from the following groups:

- a halogen selected from F, Cl, Br and I;
- a linear or branched C_1 - C_6 alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl;
- a linear or branched C_1 - C_6 alkyl-aryl group selected from $-\text{CH}_2\text{Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{F-Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{Cl-Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{Br-Ph}$, $-\text{CH}_2(2,3 \text{ or } 4)\text{I-Ph}$, $-\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$;
- a linear or branched C_1 - C_6 halogenated alkyl group selected from $-\text{CH}_2\text{F}$, $-\text{CH}_2\text{Cl}$, $-\text{CH}_2\text{Br}$, $-\text{CH}_2\text{I}$, $-\text{CF}_3$, $-\text{CCl}_3$, $-\text{CBr}_3$, $-\text{Cl}_3$, $-\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CCl}_3$, $-\text{CH}_2\text{CB}$
 r_3 , and $-\text{CH}_2\text{Cl}_3$;
- a linear or branched primary, secondary or tertiary C_1 - C_6 amine group selected from $-\text{NH}_2$, $-\text{NMeH}$, $-\text{NMe}_2$, $-\text{NEtH}$, $-\text{NEtMe}$, $-\text{NEt}_2$, $-\text{NPrH}$, $-\text{NPrMe}$, $-\text{NPrEt}$, $-\text{NPr}_2$, $-\text{NBuH}$, $-\text{NBuMe}$, $-\text{NBu}_2$, $-\text{NBu}_3$, $-\text{NMe}_3$, $-\text{NEt}_3$, $-\text{NPr}_3$, and $-\text{NBu}_3$;

NBuEt, $-\text{CH}_2\text{-NH}_2$, $-\text{CH}_2\text{-NMeH}$, $-\text{CH}_2\text{-NMe}_2$, $-\text{CH}_2\text{-NEtH}$, $-\text{CH}_2\text{-NEtMe}$, $-\text{CH}_2\text{-NEt}_2$, $-\text{CH}_2\text{-NPrH}$, $-\text{CH}_2\text{-NPrMe}$, and $-\text{CH}_2\text{-NPrEt}$;

- an amino-aryl group selected from $-\text{NH-Ph}$, $-\text{NH-(2,3 or 4)F-Ph}$, $-\text{NH-(2,3 or 4)Cl-Ph}$, $-\text{NH-(2,3 or 4)Br-Ph}$, $-\text{NH-(2,3 or 4)I-Ph}$, $-\text{NH-(2,3 or 4)Me-Ph}$, $-\text{NH-(2,3 or 4)Et-Ph}$, $-\text{NH-(2,3 or 4)Pr-Ph}$, $-\text{NH-(2,3 or 4)Bu-Ph}$, $-\text{NH-(2,3 or 4)OMe-Ph}$, $-\text{NH-(2,3 or 4)OEt-Ph}$, $-\text{NH-(2,3 or 4)OPr-Ph}$, $-\text{NH-(2,3 or 4)OBu-Ph}$, $-\text{NH-2,(3,4,5 or 6)F}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Cl}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Br}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)I}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Me}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Et}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Pr}_2\text{-Ph}$, $-\text{NH-2,(3,4,5 or 6)Bu}_2\text{-Ph}$;

- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;

- a cyclic $\text{C}_3\text{-C}_8$ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;

- a linear or branched $\text{C}_1\text{-C}_6$ alcohol group selected from $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$;

- a linear or branched $\text{C}_1\text{-C}_6$ carboxylic acid group selected from $-\text{COOH}$, $-\text{CH}_2\text{COOH}$, $-\text{CH}_2\text{CH}_2\text{COOH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{COOH}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{COOH}$;

- a linear or branched acyl group selected from $-(\text{CO})\text{Me}$, $-(\text{CO})\text{Et}$, $-(\text{CO})\text{Pr}$, $-(\text{CO})\text{iPr}$, $-(\text{CO})\text{nBu}$, $-(\text{CO})\text{iBu}$, $-(\text{CO})\text{tBu}$, $-(\text{CO})\text{Ph}$, $-(\text{CO})\text{CH}_2\text{Ph}$, $-(\text{CO})\text{CH}_2\text{OH}$, $-(\text{CO})\text{CH}_2\text{OCH}_3$, $-(\text{CO})\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{CH}_2\text{NHMe}$, $-(\text{CO})\text{CH}_2\text{NMe}_2$, $-(\text{CO})\text{-cyclopropyl}$, $-(\text{CO})\text{-1,3-epoxypropan-2-yl}$, $-(\text{CO})\text{NH}_2$, $-(\text{CO})\text{NHMe}$, $-(\text{CO})\text{NMe}_2$, $-(\text{CO})\text{NHEt}$, $-(\text{CO})\text{NEt}_2$, $-(\text{CO})\text{-pyrrolidine-N-yl}$, $-(\text{CO})\text{-morpholine-N-yl}$, $-(\text{CO})\text{-piperazine-N-yl}$, $-(\text{CO})\text{-N-methyl-piperazine-N-yl}$,

$-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OH}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OMe}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NH}_2$,
 $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NHMe}$, and $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NMe}_2$;

- a linear or branched $\text{C}_1\text{-C}_6$ carboxylic acid ester group selected from $-\text{COOMe}$, $-\text{COOEt}$, $-\text{COOPr}$, $-\text{COO-i-Pr}$, $-\text{COO-n-Bu}$, $-\text{COO-i-Bu}$, $-\text{COO-t-Bu}$, $-\text{CH}_2\text{COOMe}$, $-\text{CH}_2\text{CH}_2\text{COOMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{COOMe}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{COOMe}$;

- a linear or branched $\text{C}_1\text{-C}_6$ amide group selected from $-\text{CO-NH}_2$, $-\text{CO-NMeH}$, $-\text{CO-NMe}_2$, $-\text{CO-NEtH}$, $-\text{CO-NEtMe}$, $-\text{CO-NEt}_2$, $-\text{CO-NPrH}$, $-\text{CO-NPrMe}$, and $-\text{CO-NPrEt}$;

- a linear or branched $\text{C}_1\text{-C}_7$ amino acyl group selected from $-\text{NH-CO-Me}$, $-\text{NH-CO-Et}$, $-\text{NH-CO-Pr}$, $-\text{NH-CO-Bu}$, $-\text{NH-CO-pentyl}$, $-\text{NH-CO-hexyl}$, $-\text{NH-CO-Ph}$, $-\text{NMe-CO-Me}$, $-\text{NMe-CO-Et}$, $-\text{NMe-CO-Pr}$, $-\text{NMe-CO-Bu}$, $-\text{NMe-CO-pentyl}$, $-\text{NMe-CO-hexyl}$, $-\text{NMe-CO-Ph}$;

- a linear or branched $\text{C}_1\text{-C}_7$ alkoxy or aryloxy group selected from $-\text{OMe}$, $-\text{OEt}$, $-\text{OPr}$, $-\text{O-i-Pr}$, $-\text{O-n-Bu}$, $-\text{O-i-Bu}$, $-\text{O-t-Bu}$, $-\text{O-pentyl}$, $-\text{O-hexyl}$, $-\text{OCH}_2\text{F}$, $-\text{OCHF}_2$, $-\text{OCF}_3$, $-\text{OCH}_2\text{Cl}$, $-\text{OCHCl}_2$, $-\text{OCCl}_3$, $-\text{O-Ph}$, $-\text{O-CH}_2\text{-Ph}$, $-\text{O-CH}_2\text{-(2,3 or 4)-F-Ph}$, $-\text{O-CH}_2\text{-(2,3 or 4)-Cl-Ph}$, $-\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{OEt}$, $-\text{CH}_2\text{OPr}$, $-\text{CH}_2\text{OBu}$, $-\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$;

- a linear or branched aminoalkoxy group selected from $-\text{OCH}_2\text{NH}_2$, $-\text{OCH}_2\text{NHMe}$, $-\text{OCH}_2\text{NMe}_2$, $-\text{OCH}_2\text{NHEt}$, $-\text{OCH}_2\text{NEt}_2$, $-\text{OCH}_2\text{CH}_2\text{NH}_2$, $-\text{OCH}_2\text{CH}_2\text{NHMe}$, $-\text{OCH}_2\text{CH}_2\text{NMe}_2$, $-\text{OCH}_2\text{CH}_2\text{NHEt}$, and $-\text{OCH}_2\text{CH}_2\text{NEt}_2$;

- a sulphonyl group selected from $-\text{SO}_2\text{Me}$, $-\text{SO}_2\text{Et}$, $-\text{SO}_2\text{Pr}$, $-\text{SO}_2\text{iPr}$, $-\text{SO}_2\text{Ph}$, $-\text{SO}_2\text{-(2,3 or 4)-F-Ph}$, $-\text{SO}_2\text{-cyclopropyl}$, $-\text{SO}_2\text{CH}_2\text{CH}_2\text{OCH}_3$;

- a sulphonylamino group selected from $-\text{SO}_2\text{NH}_2$, $-\text{SO}_2\text{NHMe}$, $-\text{SO}_2\text{NMe}_2$, $-\text{SO}_2\text{NHEt}$, $-\text{SO}_2\text{NEt}_2$, $-\text{SO}_2\text{-pyrrolidine-N-yl}$, $-\text{SO}_2\text{-morpholine-N-yl}$, $-\text{SO}_2\text{NHCH}_2\text{OMe}$, and $-\text{SO}_2\text{NHCH}_2\text{CH}_2\text{OMe}$;

- an aminosulphonyl group selected from $\text{-NHSO}_2\text{Me}$, $\text{-NHSO}_2\text{Et}$, $\text{-NHSO}_2\text{Pr}$, $\text{-NHSO}_2\text{iPr}$,
 $\text{-NHSO}_2\text{Ph}$, $\text{-NHSO}_2\text{-(2,3 or 4)-F-Ph}$, $\text{-NHSO}_2\text{-cyclopropyl}$, $\text{-NHSO}_2\text{CH}_2\text{CH}_2\text{OCH}_3$;

- a cyclic aminosulphonyl- group selected from $\text{-N(SO}_2\text{)(CH}_2\text{)}_3$ and $\text{-N(SO}_2\text{)(CH}_2\text{)}_4$;

- an aromatic group selected from Ph-, 2-F-Ph-, 3-F-Ph-, 4-F-Ph-, 2-Cl-Ph-, 3-Cl-Ph-, 4-Cl-Ph-, 2-Br-Ph-, 3-Br-Ph-, 4-Br-Ph-, 2-I-Ph-, 3-I-Ph-, 4-I-Ph-, 2,(3,4,5 or 6)-F₂-Ph-, 2,(3,4,5 or 6)-Cl₂-Ph-, 2,(3,4,5 or 6)-Br₂-Ph-, 2,(3,4,5 or 6)-I₂-Ph-, 2,(3,4,5 or 6)-Me₂-Ph-, 2,(3,4,5 or 6)-Et₂-Ph-, 2,(3,4,5 or 6)-Pr₂-Ph-, 2,(3,4,5 or 6)-Bu₂-Ph-, 2,(3,4,5 or 6)-(CN)₂-Ph-, 2,(3,4,5 or 6)-(NO₂)₂-Ph-, 2,(3,4,5 or 6)-(NH₂)₂-Ph-, 2,(3,4,5 or 6)-(MeO)₂-Ph-, 2,(3,4,5 or 6)-(CF₃)₂-Ph-, 3,(4 or 5)-F₂-Ph-, 3,(4 or 5)-Cl₂-Ph-, 3,(4 or 5)-Br₂-Ph-, 3,(4 or 5)-I₂-Ph-, 3,(4 or 5)-Me₂-Ph-, 3,(4 or 5)-Et₂-Ph-, 3,(4 or 5)-Pr₂-Ph-, 3,(4 or 5)-Bu₂-Ph-, 3,(4 or 5)-(CN)₂-Ph-, 3,(4 or 5)-(NO₂)₂-Ph-, 3,(4 or 5)-(NH₂)₂-Ph-, 3,(4 or 5)-(MeO)₂-Ph-, 3,(4 or 5)-(CF₃)₂-Ph-, 2-Me-Ph-, 3-Me-Ph-, 4-Me-Ph-, 2-Et-Ph-, 3-Et-Ph-, 4-Et-Ph-, 2-Pr-Ph-, 3-Pr-Ph-, 4-Pr-Ph-, 2-Bu-Ph-, 3-Bu-Ph-, 4-Bu-Ph-, 2-(CN)-Ph-, 3-(CN)-Ph-, 4-(CN)-Ph-, 2-(NO₂)-Ph-, 3-(NO₂)-Ph-, 4-(NO₂)-Ph-, 2-(NH₂)-Ph-, 3-(NH₂)-Ph-, 4-(NH₂)-Ph-, 2-MeO-Ph-, 3-MeO-Ph-, 4-MeO-Ph-, 2-(NH₂-CO)-Ph-, 3-(NH₂-CO)-Ph-, 4-(NH₂-CO)-Ph-, 2-CF₃-Ph-, 3-CF₃-Ph-, 4-CF₃-Ph-, 2- CF₃O-Ph-, 3- CF₃O-Ph-, and 4- CF₃O-Ph-; and

- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl.

6. A compound according to any preceding claim, wherein each of R⁷¹, or R⁷² is independently H or a group selected from the following groups:

- a halogen selected from F, Cl, Br and I;

- a linear or branched C₁-C₆ alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl;
- a linear or branched C₁-C₆ alkyl-aryl group selected from -CH₂Ph, -CH₂(2,3 or 4)F-Ph, -CH₂(2,3 or 4)Cl-Ph, -CH₂(2,3 or 4)Br-Ph, -CH₂(2,3 or 4)I-Ph, -CH₂CH₂Ph, -CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂CH₂Ph, and -CH₂CH₂CH₂CH₂CH₂CH₂Ph;
- a linear or branched C₁-C₆ halogenated alkyl group selected from -CH₂F, -CH₂Cl, -CH₂Br, -CH₂I, -CF₃, -CCl₃, -CBr₃, -CI₃, -CH₂CF₃, -CH₂CCl₃, -CH₂CB_{r3}, and -CH₂CI₃;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group selected from -NH₂, -NMeH, -NMe₂, -NEtH, -NEtMe, -NEt₂, -NPrH, -NPrMe, -NPrEt, -NPr₂, -NBuH, -NBuMe, -NBuEt, -CH₂-NH₂, -CH₂-NMeH, -CH₂-NMe₂, -CH₂-NEtH, -CH₂-NEtMe, -CH₂-NEt₂, -CH₂-NPrH, -CH₂-NPrMe, and -CH₂-NPrEt;
- an amino-aryl group selected from -NH-Ph, -NH-(2,3 or 4)F-Ph, -NH-(2,3 or 4)Cl-Ph, -NH-(2,3 or 4)Br-Ph, -NH-(2,3 or 4)I-Ph, -NH-(2,3 or 4)Me-Ph, -NH-(2,3 or 4)Et-Ph, -NH-(2,3 or 4)Pr-Ph, -NH-(2,3 or 4)Bu-Ph, -NH-(2,3 or 4)OMe-Ph, -NH-(2,3 or 4)OEt-Ph, -NH-(2,3 or 4)OPr-Ph, -NH-(2,3 or 4)OBu-Ph, -NH-2,(3,4,5 or 6)F₂-Ph, -NH-2,(3,4,5 or 6)Cl₂-Ph, -NH-2,(3,4,5 or 6)Br₂-Ph, -NH-2,(3,4,5 or 6)I₂-Ph, -NH-2,(3,4,5 or 6)Me₂-Ph, -NH-2,(3,4,5 or 6)Et₂-Ph, -NH-2,(3,4,5 or 6)Pr₂-Ph, -NH-2,(3,4,5 or 6)Bu₂-Ph;
- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C₃-C₈ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;

- a linear or branched C₁-C₆ alcohol group selected from -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂CH₂OH, and -CH₂CH₂CH₂CH₂CH₂CH₂OH;

- a linear or branched C₁-C₆ carboxylic acid group selected from -COOH, -CH₂COOH, -CH₂CH₂COOH, -CH₂CH₂CH₂COOH, -CH₂CH₂CH₂CH₂COOH, and -CH₂CH₂CH₂CH₂CH₂COOH;

- a linear or branched acyl group selected from -(CO)Me, -(CO)Et, -(CO)Pr, -(CO)iPr, -(CO)nBu, -(CO)iBu, -(CO)tBu, -(CO)Ph, -(CO)CH₂Ph, -(CO)CH₂OH, -(CO)CH₂OCH₃, -(CO)CH₂NH₂, -(CO)CH₂NHMe, -(CO)CH₂NMe₂, -(CO)-cyclopropyl, -(CO)-1,3-epoxypropan-2-yl; -(CO)NH₂, -(CO)NHMe, -(CO)NMe₂, -(CO)NH₂Et, -(CO)NEt₂, -(CO)-pyrrolidine-N-yl, -(CO)-morpholine-N-yl, -(CO)-piperazine-N-yl, -(CO)-N-methyl-piperazine-N-yl, -(CO)NHCH₂CH₂OH, -(CO)NHCH₂CH₂OMe, -(CO)NHCH₂CH₂NH₂, -(CO)NHCH₂CH₂NHMe, and -(CO)NHCH₂CH₂NMe₂;

- a linear or branched C₁-C₆ carboxylic acid ester group selected from -COOMe, -COOEt, -COOPr, -COO-i-Pr, -COO-n-Bu, -COO-i-Bu, -COO-t-Bu, -CH₂COOMe, -CH₂CH₂COOMe, -CH₂CH₂CH₂COOMe, and -CH₂CH₂CH₂CH₂COOMe;

- a linear or branched C₁-C₆ amide group selected from -CO-NH₂, -CO-NMeH, -CO-NMe₂, -CO-NEtH, -CO-NEtMe, -CO-NEt₂, -CO-NPrH, -CO-NPrMe, and -CO-NPrEt;

- a linear or branched C₁-C₇ amino acyl group selected from -NH-CO-Me, -NH-CO-Et, -NH-CO-Pr, -NH-CO-Bu, -NH-CO-pentyl, -NH-CO-hexyl, -NH-CO-Ph, -NMe-CO-Me, -NMe-CO-Et, -NMe-CO-Pr, -NMe-CO-Bu, -NMe-CO-pentyl, -NMe-CO-hexyl, -NMe-CO-Ph;

- a linear or branched C₁-C₇ alkoxy or aryloxy group selected from -OMe, -OEt, -OPr, -O-i-Pr, -O-n-Bu, -O-i-Bu, -O-t-Bu, -O-pentyl, -O-hexyl, -OCH₂F, -OCHF₂, -OCF₃, -OCH₂Cl, -OCHCl₂, -OCCl₃, -O-Ph, -O-CH₂-Ph, -O-CH₂-(2,3 or 4)-F-Ph, -O-CH₂-(2,3 or 4)-Cl-Ph, -

CH₂OMe, -CH₂OEt, -CH₂OPr, -CH₂OBu, -CH₂CH₂OMe, -CH₂CH₂CH₂OMe, -CH₂CH₂CH₂CH₂OMe, and -CH₂CH₂CH₂CH₂CH₂OMe;

- a linear or branched aminoalkoxy group selected from -OCH₂NH₂, -OCH₂NHMe, -OCH₂NMe₂, -OCH₂NHEt, -OCH₂NEt₂, -OCH₂CH₂NH₂, -OCH₂CH₂NHMe, -OCH₂CH₂NMe₂, -OCH₂CH₂NHEt, and -OCH₂CH₂NEt₂;

- a sulphonyl group selected from -SO₂Me, -SO₂Et, -SO₂Pr, -SO₂iPr, -SO₂Ph, -SO₂-(2,3 or 4)-F-Ph, -SO₂-cyclopropyl, -SO₂CH₂CH₂OCH₃;

- a sulphonylamino group selected from -SO₂NH₂, -SO₂NHMe, -SO₂NMe₂, -SO₂NHEt, -SO₂NEt₂, -SO₂-pyrrolidine-N-yl, -SO₂-morpholine-N-yl, -SO₂NHCH₂OMe, and -SO₂NHCH₂CH₂OMe;

- an aminosulphonyl group selected from -NHSO₂Me, -NHSO₂Et, -NHSO₂Pr, -NHSO₂iPr, -NHSO₂Ph, -NHSO₂-(2,3 or 4)-F-Ph, -NHSO₂-cyclopropyl, -NHSO₂CH₂CH₂OCH₃;

- a cyclic aminosulphonyl- group selected from -N(SO₂)(CH₂)₃ and -N(SO₂)(CH₂)₄;

- an aromatic group selected from Ph-, 2-F-Ph-, 3-F-Ph-, 4-F-Ph-, 2-Cl-Ph-, 3-Cl-Ph-, 4-Cl-Ph-, 2-Br-Ph-, 3-Br-Ph-, 4-Br-Ph-, 2-I-Ph-, 3-I-Ph-, 4-I-Ph-, 2,(3,4,5 or 6)-F₂-Ph-, 2,(3,4,5 or 6)-Cl₂-Ph-, 2,(3,4,5 or 6)-Br₂-Ph-, 2,(3,4,5 or 6)-I₂-Ph-, 2,(3,4,5 or 6)-Me₂-Ph-, 2,(3,4,5 or 6)-Et₂-Ph-, 2,(3,4,5 or 6)-Pr₂-Ph-, 2,(3,4,5 or 6)-Bu₂-Ph-, 2,(3,4,5 or 6)-(CN)₂-Ph-, 2,(3,4,5 or 6)-(NO₂)₂-Ph-, 2,(3,4,5 or 6)-(NH₂)₂-Ph-, 2,(3,4,5 or 6)-(MeO)₂-Ph-, 2,(3,4,5 or 6)-(CF₃)₂-Ph-, 3,(4 or 5)-F₂-Ph-, 3,(4 or 5)-Cl₂-Ph-, 3,(4 or 5)-Br₂-Ph-, 3,(4 or 5)-I₂-Ph-, 3,(4 or 5)-Me₂-Ph-, 3,(4 or 5)-Et₂-Ph-, 3,(4 or 5)-Pr₂-Ph-, 3,(4 or 5)-Bu₂-Ph-, 3,(4 or 5)-(CN)₂-Ph-, 3,(4 or 5)-(NO₂)₂-Ph-, 3,(4 or 5)-(NH₂)₂-Ph-, 3,(4 or 5)-(MeO)₂-Ph-, 3,(4 or 5)-(CF₃)₂-Ph-, 2-Me-Ph-, 3-Me-Ph-, 4-Me-Ph-, 2-Et-Ph-, 3-Et-Ph-, 4-Et-Ph-, 2-Pr-Ph-, 3-Pr-Ph-, 4-Pr-Ph-, 2-Bu-Ph-, 3-Bu-Ph-, 4-Bu-Ph-, 2-(CN)-Ph-, 3-(CN)-Ph-, 4-(CN)-Ph-, 2-(NO₂)-Ph-, 3-(NO₂)-Ph-, 4-(NO₂)-Ph-, 2-(NH₂)-Ph-, 3-(NH₂)-Ph-, 4-(NH₂)-Ph-, 2-MeO-Ph-, 3-MeO-Ph-, 4-MeO-Ph-, 2-(NH₂-CO)-Ph-, 3-(NH₂-CO)-Ph-, 4-(NH₂-CO)-Ph-, 2-CF₃-Ph-, 3-CF₃-Ph-, 4-CF₃-Ph-, 2-CF₃O-Ph-, 3-CF₃O-Ph-, and 4-CF₃O-Ph-; and

- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1-yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl;

or wherein two of R⁷² when attached to the same carbon atom may together form a ketone group.

7. A compound according to any of the preceding claims, wherein:

R³ is selected from the following:

- an unsubstituted, 2-monosubstituted, or 2,6-disubstituted phenyl group selected from Ph-, 2-F-Ph-, 2,6-F₂-Ph-, 2-Cl-Ph-, 2,6-Cl₂-Ph-, 2-CN-Ph-, 2,6-(CN)₂-Ph-, 2,6-F,CN-Ph-, 2,6-F,Cl-Ph-, and 2,6-Cl,CN-Ph-;

- an unsubstituted or 3-monosubstituted pyridine-2-yl, or a 2,6-disubstituted pyridine-4-yl group selected from Pyr-2-yl, Pyr-3-yl, Pyr-4-yl, 3-F-Pyr-2-yl, 3-Cl-Pyr-2-yl, 3-CN-Pyr-2-yl, 2,6-F₂-Pyr-4-yl, 2,6-Cl₂-Pyr-4-yl and 2,6-(CN)₂-Pyr-4-yl; wherein Pyr means pyridin;

- an unsubstituted or 4-substituted pyridazin-3-yl group selected from pyridazine-3-yl, 4-F-pyridazine-3-yl, 4-Cl-pyridazine-3-yl, and 4-CN-pyridazine-3-yl;

- a substituted or unsubstituted 1,2,4-oxadiazol-3-yl group;

- a cyclic aminosulphonyl- group selected from -N(SO₂)(CH₂)₃ and -N(SO₂)(CH₂)₄;

- a linear or branched aminosulphonyl group selected from $-\text{NH}-\text{SO}_2-\text{Me}$, $-\text{NH}-\text{SO}_2-\text{Et}$, $-\text{NH}-\text{SO}_2-\text{iPr}$, $-\text{NH}-\text{SO}_2-\text{cycloPr}$, $-\text{NH}-\text{SO}_2-\text{Pr}$, $-\text{NH}-\text{SO}_2-\text{EtOMe}$, $-\text{NMe}-\text{SO}_2-\text{Me}$, $-\text{NMe}-\text{SO}_2-\text{Et}$, $-\text{NMe}-\text{SO}_2-\text{iPr}$, $-\text{NMe}-\text{SO}_2-\text{cycloPr}$, $-\text{NMe}-\text{SO}_2-\text{Pr}$, $-\text{NMe}-\text{SO}_2-\text{EtOMe}$, $-\text{NEt}-\text{SO}_2-\text{Me}$, $-\text{NEt}-\text{SO}_2-\text{Et}$, $-\text{NEt}-\text{SO}_2-\text{iPr}$, $-\text{NEt}-\text{SO}_2-\text{cycloPr}$, $-\text{NEt}-\text{SO}_2-\text{Pr}$, $-\text{NEt}-\text{SO}_2-\text{EtOMe}$, $-\text{NiPr}-\text{SO}_2-\text{Me}$, $-\text{NiPr}-\text{SO}_2-\text{Et}$, $-\text{NiPr}-\text{SO}_2-\text{iPr}$, $-\text{NiPr}-\text{SO}_2-\text{cycloPr}$, $-\text{NiPr}-\text{SO}_2-\text{Pr}$, $-\text{NiPr}-\text{SO}_2-\text{EtOMe}$, $-\text{N}(\text{CHF}_2)-\text{SO}_2-\text{Me}$, $-\text{N}(\text{CHF}_2)-\text{SO}_2-\text{Et}$, $-\text{N}(\text{CHF}_2)-\text{SO}_2-\text{iPr}$, $-\text{N}(\text{CHF}_2)-\text{SO}_2-\text{cycloPr}$, $-\text{N}(\text{CHF}_2)-\text{SO}_2-\text{Pr}$, and $-\text{N}(\text{CHF}_2)-\text{SO}_2-\text{EtOMe}$;

- a linear or branched sulphonylamino group selected from $-\text{SO}_2-\text{NH}_2$, $-\text{SO}_2-\text{NHMe}$, $-\text{SO}_2-\text{NHEt}$, $-\text{SO}_2-\text{NMe}_2$, $-\text{SO}_2-\text{NMeEt}$, $-\text{SO}_2-\text{NHEt}_2$, and $-\text{SO}_2-\text{pyrrolidin-N-yl}$;

- a linear or branched sulphonyl group selected from $-\text{SO}_2\text{Me}$, $-\text{SO}_2\text{Et}$, $-\text{SO}_2\text{Pr}$, $-\text{SO}_2\text{iPr}$;

- a thioether group selected from $-\text{SMe}$, $-\text{SEt}$, $-\text{SPr}$, and SiPr ;

- a branched or cyclic alkyl or alkenyl group having 3 carbon atoms or more selected from an isopropyl, a cyclopropyl and a propen-2-yl group;


R^6 is selected from the following:

- an unsubstituted, 2-,3- or 4-monosubstituted, and a 2,4 or 3,4-disubstituted phenyl group selected from 2-F-Ph, 2-Cl-Ph, 2-OMe-Ph, 3-F-Ph, 3-Cl-Ph, 3-OMe-Ph, 4-F-Ph, 4-Cl-Ph, 4-OMe-Ph, 2,4-F₂-Ph, 2,4-Cl₂-Ph, 2,4-(OMe)₂-Ph, 3,4-F₂-Ph, 3,4-Cl₂-Ph, and 3,4-(OMe)₂-Ph;


- a substituted or unsubstituted pyridine-2-yl, pyridine-3-yl or pyridine-4-yl group selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 3-F-pyridin-2-yl, 3-Cl-pyridin-2-yl, 4-F-pyridin-2-yl, 4-Cl-pyridin-2-yl, 5-F-pyridin-2-yl, 5-Cl-pyridin-2-yl;

- a cyclic ether group selected from tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl and tetrahydropyran-4-yl; and


the group:




is selected from the following groups:



and also from a group having the following structure:



wherein the ring fused to the piperazine ring is a 5- or 6-membered ring optionally having 1 or more further heteroatoms in the ring selected from N and O and optionally having one or more substituents, preferably wherein this group is selected from the following:











wherein







- R^{792} is selected from Me, Et, Pr, iPr, cyPr, cyBu, $-(CO)-Me$, $-(CO)-Et$, $-(CO)-Pr$, $-(CO)iPr$, $-SO_2Me$, and SO_2Et ;


- R^{793} is selected from Me, Et, Pr, iPr, cyPr, cyBu, $-(CO)-Me$, $-(CO)Et$, $-(CO)Pr$, and $-(CO)iPr$;

- R⁷⁹⁴ is selected from H, Me, Et, Pr, iPr, cyPr, cyBu; an unsubstituted, 2-,3- or 4-monosubstituted, and a 2,4 or 3,4-disubstituted phenyl group selected from 2-F-Ph, 2-Cl-Ph, 2-CN-Ph, 2-OMe-Ph, 3-F-Ph, 3-Cl-Ph, 3-CN-Ph, 3-OMe-Ph, 4-F-Ph, 4-Cl-Ph, 4-CN-Ph, 4-OMe-Ph, 2,4-F₂-Ph, 2,4-Cl₂-Ph, 2,4-(CN)₂-Ph, 2,4-(OMe)₂-Ph, 3,4-F₂-Ph, 3,4-Cl₂-Ph, 3,4-(CN)₂-Ph, and 3,4-(OMe)₂-Ph); -NH₂, -NHMe, and -NMe₂; -OH, -OMe, -OEt, -OPr, -OiPr, -OⁿBu, and -O^tBu; -CH₂OH, -CHMeOH, -C(Me)₂OH, -CH₂OMe, -CHMeOMe, -C(Me)₂OMe, -CH₂OEt, -CHMeOEt, and -C(Me)₂OEt; and a heterocyclic ring group having from 4-7 ring atoms with at least one heteroatom selected from N, O, and S, wherein the ring group is selected from the following groups:











8. A compound according to any of the preceding claims, wherein R^{73} is an acyl group; and wherein R^1 is H, R^2 is H, R^4 is H or Me, each R^{71} is H, and each R^{72} is H.


9. A compound according to any of the preceding claims, wherein R^{73} is an acyl group; and wherein X is N; and wherein R^1 is H, R^2 is H, R^4 is H or Me, R^6 is not H, each R^{71} is H, and each R^{72} is H.

10. A compound according to any preceding claim, wherein the compound is selected from the group consisting of:







19




20




21




22




23




24





25




26









40




41




42




43




44




45




46




47




48




49




50




51




52




53




54




55







64




65




66




67




68




69




70




71




72




74




76




78




79




80




81




82




83




84




85




86




87




88




90




91




92




93




94




95




96




99




100




101




102





103




104









122




124




125




126




127




128




129




131




132




133




134




137




138




139




140




141




142




143




144




145




147




148




149




150




151




152




153




154




155




156




157




158




159




162




163




166




170




171




172




173




174




175




176




177




178




179




180




181




183




184




185




189




190




191




192




193




194




195




196




199




200




201




202




203




204




205




206




207




211




212




213




214




215




218




219




220




221



222




223




225


227




226




229




230




233




234




235




236




237




240




241




242




243




244




246




247




248




249




250




251




252




257




258




259




260




262




263




264











266




270




275







285




286




287




290




292




293




295




298




299




301




303




305




307




308




309




310




312




313




314




315




316




317




318




319




320




324




326




327




328




329




332




333




334




335




336




337




338




339




340




341




342




343




345




346




350




351




353




354




356




357




360




361




363




365




367




368




369




370




372




375



376



377




11. A pharmaceutical composition comprising a compound as defined in any of claims 1-10 and a carrier.

12. The pharmaceutical composition according to claim 11, further comprising a pharmaceutically acceptable additive and/or excipient.

13. The pharmaceutical composition according to claim 11 or claim 12, for use in treating a cancer, an inflammatory condition, an autoimmune condition, a neurological condition, a proliferative disorder and/or a metabolic condition in a patient.

14. The pharmaceutical composition according to claim 13 for use in treating a cancer, further comprising a further agent for treating cancer; preferably wherein the further agent for treating cancer is selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormone analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, respiratory chain un-couplers such as metformin, and cell cycle signalling inhibitors.

15. A compound, wherein the compound is of the following formula:



wherein in (I) the substituents are selected from one of the following groups (i)-(iv):

(i) R^3 is selected from a saturated carbocyclic ring having from 3 to 7 ring carbons; and an aromatic ring having from 3 to 7 ring carbons provided that it is not a 4-methylphenyl group;

R^6 is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms; X is N;

R^{73} is a $-(CO)-R^{75}$ group;

wherein R^1 , R^2 , and R^4 are independently selected from H and a group selected from the following groups

- a halogen;
- a linear or branched C_1-C_6 alkyl group;
- a linear or branched C_1-C_6 alkyl-aryl group;
- a linear or branched C_1-C_6 halogenated alkyl group;
- a linear or branched primary, secondary or tertiary C_1-C_6 amine group;
- an amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C_3-C_8 alkyl group;
- a linear or branched C_1-C_6 alcohol group;
- a linear or branched C_1-C_6 carboxylic acid group;
- a linear or branched acyl group;
- a linear or branched C_1-C_6 carboxylic acid ester group;
- a linear or branched C_1-C_6 amide group;
- a linear or branched C_1-C_7 amino acyl group;
- a linear or branched C_1-C_7 alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group; and
- a saturated or unsaturated heterocyclic group; and

wherein each of R^{71} , R^{72} and R^{75} is independently H or a group selected from the following groups:

- a halogen;
- a linear or branched C_1-C_6 alkyl group;

- a linear or branched C₁-C₆ alkyl-aryl group;
- a linear or branched C₁-C₆ halogenated alkyl group;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group;
- an amino-aryl group;
- a cyclic amino or amido group;
- a cyclic C₃-C₈ alkyl group;
- a linear or branched C₁-C₆ alcohol group;
- a linear or branched acyl group;
- a linear or branched C₁-C₆ carboxylic acid ester group;
- a linear or branched C₁-C₆ amide group;
- a linear or branched C₁-C₇ amino acyl group;
- a linear or branched C₁-C₇ alkoxy or aryloxy group;
- a linear or branched aminoalkoxy group;
- a sulphonyl group;
- a sulphonamido group;
- an aminosulphonyl group;
- a cyclic aminosulphonyl- group; and
- a saturated or unsaturated heterocyclic group;

(ii) R³ is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms;

R⁶ is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms;

X is independently selected from N, O and S; wherein R⁷³ is absent when its X is O or S; and

wherein R¹, R², R⁴, R⁷¹, R⁷² and R⁷³ are as defined in section (i) above;

(iii) R³ is a -Z(R³³)₂ group in which Z is C ;

R³³ is selected from a linear or branched alkyl group optionally forming a non-aromatic carbocyclic or heterocyclic ring with another R³³, a substituted sulphonyl group, and an acyl

group; provided that the $-Z(R^{33})_2$ group is not $-NH_2$ or an amide bonded to the ring via a C atom;

R^6 is a saturated or unsaturated heterocyclic group having from 4 to 7 ring atoms; X is N; and wherein R^{73} is a $-(CO)-R^{75}$ group; and

wherein $R^1, R^2, R^4, R^{71}, R^{72}$ and R^{75} are as defined under section (i) above;

(iv) R^6 is a saturated homocyclic or heterocyclic group having from 3-7 ring atoms in which each ring atom is selected from C, N, O or S, provided that R^6 is not adamantyl;

X is independently selected from N, O and S; wherein R^{73} is absent when its X is O or S; and

wherein $R^1, R^2, R^3, R^4, R^{71}, R^{72}$ and R^{73} are as defined under section (i) above.

16. A compound according to claim 15, wherein R^3 is a group selected from the following groups:

- a linear or branched C_1 - C_6 alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl; preferably a C_3 - C_6 alkyl group (such as propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl);
- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C_3 - C_8 alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;

- a linear or branched acyl group selected from $-(\text{CO})\text{Me}$, $-(\text{CO})\text{Et}$, $-(\text{CO})\text{Pr}$, $-(\text{CO})\text{iPr}$, $-(\text{CO})\text{nBu}$, $-(\text{CO})\text{iBu}$, $-(\text{CO})\text{tBu}$, $-(\text{CO})\text{Ph}$, $-(\text{CO})\text{CH}_2\text{Ph}$, $-(\text{CO})\text{CH}_2\text{OH}$, $-(\text{CO})\text{CH}_2\text{OCH}_3$, $-(\text{CO})\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{CH}_2\text{NHMe}$, $-(\text{CO})\text{CH}_2\text{NMe}_2$, $-(\text{CO})\text{-cyclopropyl}$, $-(\text{CO})\text{-1,3-epoxypropan-2-yl}$; $-(\text{CO})\text{NH}_2$, $-(\text{CO})\text{NHMe}$, $-(\text{CO})\text{NMe}_2$, $-(\text{CO})\text{NHEt}$, $-(\text{CO})\text{NEt}_2$, $-(\text{CO})\text{-pyrrolidine-N-yl}$, $-(\text{CO})\text{-morpholine-N-yl}$, $-(\text{CO})\text{-piperazine-N-yl}$, $-(\text{CO})\text{-N-methyl-piperazine-N-yl}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OH}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OMe}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NHMe}$, and $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NMe}_2$;

- a sulphonyl group selected from $-\text{SO}_2\text{Me}$, $-\text{SO}_2\text{Et}$, $-\text{SO}_2\text{Pr}$, $-\text{SO}_2\text{iPr}$, $-\text{SO}_2\text{Ph}$, $-\text{SO}_2\text{-(2,3 or 4)-F-Ph}$, $-\text{SO}_2\text{-cyclopropyl}$, $-\text{SO}_2\text{CH}_2\text{CH}_2\text{OCH}_3$;

- an aromatic group selected from Ph- , 2-F-Ph- , 3-F-Ph- , 4-F-Ph- , 2-Cl-Ph- , 3-Cl-Ph- , 4-Cl-Ph- , 2-Br-Ph- , 3-Br-Ph- , 4-Br-Ph- , 2-I-Ph- , 3-I-Ph- , 4-I-Ph- , $2\text{,(3,4,5 or 6)-F}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-Cl}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-Br}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-I}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-Me}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-Et}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-Pr}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-Bu}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-(CN)}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-(NO}_2)_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-(NH}_2)_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-(MeO)}_2\text{-Ph-}$, $2\text{,(3,4,5 or 6)-(CF}_3)_2\text{-Ph-}$, $3\text{,(4 or 5)-F}_2\text{-Ph-}$, $3\text{,(4 or 5)-Cl}_2\text{-Ph-}$, $3\text{,(4 or 5)-Br}_2\text{-Ph-}$, $3\text{,(4 or 5)-I}_2\text{-Ph-}$, $3\text{,(4 or 5)-Me}_2\text{-Ph-}$, $3\text{,(4 or 5)-Et}_2\text{-Ph-}$, $3\text{,(4 or 5)-Pr}_2\text{-Ph-}$, $3\text{,(4 or 5)-Bu}_2\text{-Ph-}$, $3\text{,(4 or 5)-(CN)}_2\text{-Ph-}$, $3\text{,(4 or 5)-(NO}_2)_2\text{-Ph-}$, $3\text{,(4 or 5)-(NH}_2)_2\text{-Ph-}$, $3\text{,(4 or 5)-(MeO)}_2\text{-Ph-}$, $3\text{,(4 or 5)-(CF}_3)_2\text{-Ph-}$, 2-Me-Ph- , 3-Me-Ph- , 2-Et-Ph- , 3-Et-Ph- , 4-Et-Ph- , 2-Pr-Ph- , 3-Pr-Ph- , 4-Pr-Ph- , 2-Bu-Ph- , 3-Bu-Ph- , 4-Bu-Ph- , 2-(CN)-Ph- , 3-(CN)-Ph- , 4-(CN)-Ph- , $2\text{-(NO}_2\text{)-Ph-}$, $3\text{-(NO}_2\text{)-Ph-}$, $4\text{-(NO}_2\text{)-Ph-}$, $2\text{-(NH}_2\text{)-Ph-}$, $3\text{-(NH}_2\text{)-Ph-}$, $4\text{-(NH}_2\text{)-Ph-}$, 2-MeO-Ph- , 3-MeO-Ph- , 4-MeO-Ph- , $2\text{-(NH}_2\text{-CO)-Ph-}$, $3\text{-(NH}_2\text{-CO)-Ph-}$, $4\text{-(NH}_2\text{-CO)-Ph-}$, $2\text{-CF}_3\text{-Ph-}$, $3\text{-CF}_3\text{-Ph-}$, $4\text{-CF}_3\text{-Ph-}$, $2\text{-CF}_3\text{O-Ph-}$, $3\text{-CF}_3\text{O-Ph-}$, and $4\text{-CF}_3\text{O-Ph-}$; and

- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl , pyridin-2-yl , pyridin-3-yl , pyridin-4-yl , thiophen-1-yl , thiophen-2-yl , thiophen-3-yl , pyrimidin-1-yl , pyrimidin-2-yl , pyrimidin-3-yl , pyrimidin-4-yl , pyrimidin-5-yl , pyrimidin-6-yl , tetrazole-1-yl , tetrazole-2-yl , tetrazole-3-yl , tetrazole-4-yl , tetrazole-5-yl , $\text{(1,3,4-oxadiazol)-1-yl}$, $\text{(1,3,4-oxadiazol)-2-yl}$, $\text{(1,3,4-oxadiazol)-3-yl}$, $\text{(1,3,4-oxadiazol)-4-yl}$, $\text{(1,3,4-oxadiazol)-5-yl}$, $\text{(1,2,4-oxadiazol)-1-yl}$, $\text{(1,2,4-oxadiazol)-2-yl}$, $\text{(1,2,4-oxadiazol)-3-yl}$, $\text{(1,2,4-oxadiazol)-4-yl}$, $\text{(1,2,4-oxadiazol)-5-yl}$;

yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl;

wherein R⁶ is a group selected from the following groups:

- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C₃-C₈ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
- a cyclic aminosulphonyl- group selected from -N(SO₂)(CH₂)₃ and -N(SO₂)(CH₂)₄;
- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1-yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl;

wherein R¹, R², and R⁴ are each independently H or a group selected from the following groups:

- a halogen selected from F, Cl, Br and I;
- a linear or branched C₁-C₆ alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl;

- a linear or branched C₁-C₆ alkyl-aryl group selected from -CH₂Ph, -CH₂(2,3 or 4)F-Ph, -CH₂(2,3 or 4)Cl-Ph, -CH₂(2,3 or 4)Br-Ph, -CH₂(2,3 or 4)I-Ph, -CH₂CH₂Ph, -CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂CH₂Ph, and -CH₂CH₂CH₂CH₂CH₂CH₂Ph;
- a linear or branched C₁-C₆ halogenated alkyl group selected from -CH₂F, -CH₂Cl, -CH₂Br, -CH₂I, -CF₃, -CCl₃, -CBr₃, -CI₃, -CH₂CF₃, -CH₂CCl₃, -CH₂CB_{r3}, and -CH₂Cl₃;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group selected from -NH₂, -NMeH, -NMe₂, -NEtH, -NEtMe, -NEt₂, -NPrH, -NPrMe, -NPrEt, -NPr₂, -NBuH, -NBuMe, -NBuEt, -CH₂-NH₂, -CH₂-NMeH, -CH₂-NMe₂, -CH₂-NEtH, -CH₂-NEtMe, -CH₂-NEt₂, -CH₂-NPrH, -CH₂-NPrMe, and -CH₂-NPrEt;
- an amino-aryl group selected from -NH-Ph, -NH-(2,3 or 4)F-Ph, -NH-(2,3 or 4)Cl-Ph, -NH-(2,3 or 4)Br-Ph, -NH-(2,3 or 4)I-Ph, -NH-(2,3 or 4)Me-Ph, -NH-(2,3 or 4)Et-Ph, -NH-(2,3 or 4)Pr-Ph, -NH-(2,3 or 4)Bu-Ph, -NH-(2,3 or 4)OMe-Ph, -NH-(2,3 or 4)OEt-Ph, -NH-(2,3 or 4)OPr-Ph, -NH-(2,3 or 4)OBu-Ph, -NH-2,(3,4,5 or 6)F₂-Ph, -NH-2,(3,4,5 or 6)Cl₂-Ph, -NH-2,(3,4,5 or 6)Br₂-Ph, -NH-2,(3,4,5 or 6)I₂-Ph, -NH-2,(3,4,5 or 6)Me₂-Ph, -NH-2,(3,4,5 or 6)Et₂-Ph, -NH-2,(3,4,5, or 6)Pr₂-Ph, -NH-2,(3,4,5 or 6)Bu₂-Ph;
- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C₃-C₈ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
- a linear or branched C₁-C₆ alcohol group selected from -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂CH₂OH, and -CH₂CH₂CH₂CH₂CH₂CH₂OH;

- a linear or branched C₁-C₆ carboxylic acid group selected from -COOH, -CH₂COOH, -CH₂CH₂COOH, -CH₂CH₂CH₂COOH, -CH₂CH₂CH₂CH₂COOH, and -CH₂CH₂CH₂CH₂CH₂COOH;

- a linear or branched acyl group selected from -(CO)Me, -(CO)Et, -(CO)Pr, -(CO)iPr, -(CO)nBu, -(CO)iBu, -(CO)tBu, -(CO)Ph, -(CO)CH₂Ph, -(CO)CH₂OH, -(CO)CH₂OCH₃, -(CO)CH₂NH₂, -(CO)CH₂NHMe, -(CO)CH₂NMe₂, -(CO)-cyclopropyl, -(CO)-1,3-epoxypropan-2-yl, -(CO)NH₂, -(CO)NHMe, -(CO)NMe₂, -(CO)NH₂Et, -(CO)NEt₂, -(CO)-pyrrolidine-N-yl, -(CO)-morpholine-N-yl, -(CO)-piperazine-N-yl, -(CO)-N-methyl-piperazine-N-yl, -(CO)NHCH₂CH₂OH, -(CO)NHCH₂CH₂OMe, -(CO)NHCH₂CH₂NH₂, -(CO)NHCH₂CH₂NHMe, and -(CO)NHCH₂CH₂NMe₂;

- a linear or branched C₁-C₆ carboxylic acid ester group selected from -COOMe, -COOEt, -COOPr, -COO-i-Pr, -COO-n-Bu, -COO-i-Bu, -COO-t-Bu, -CH₂COOMe, -CH₂CH₂COOMe, -CH₂CH₂CH₂COOMe, and -CH₂CH₂CH₂CH₂COOMe;

- a linear or branched C₁-C₆ amide group selected from -CO-NH₂, -CO-NMeH, -CO-NMe₂, -CO-NEtH, -CO-NEtMe, -CO-NEt₂, -CO-NPrH, -CO-NPrMe, and -CO-NPrEt;

- a linear or branched C₁-C₇ amino acyl group selected from -NH-CO-Me, -NH-CO-Et, -NH-CO-Pr, -NH-CO-Bu, -NH-CO-pentyl, -NH-CO-hexyl, -NH-CO-Ph, -NMe-CO-Me, -NMe-CO-Et, -NMe-CO-Pr, -NMe-CO-Bu, -NMe-CO-pentyl, -NMe-CO-hexyl, -NMe-CO-Ph;

- a linear or branched C₁-C₇ alkoxy or aryloxy group selected from -OMe, -OEt, -OPr, -O-i-Pr, -O-n-Bu, -O-i-Bu, -O-t-Bu, -O-pentyl, -O-hexyl, -OCH₂F, -OCHF₂, -OCF₃, -OCH₂Cl, -OCHCl₂, -OCCl₃, -O-Ph, -O-CH₂-Ph, -O-CH₂-(2,3 or 4)-F-Ph, -O-CH₂-(2,3 or 4)-Cl-Ph, -CH₂OMe, -CH₂OEt, -CH₂OPr, -CH₂OBu, -CH₂CH₂OMe, -CH₂CH₂CH₂OMe, -CH₂CH₂CH₂CH₂OMe, and -CH₂CH₂CH₂CH₂CH₂OMe;

- a linear or branched aminoalkoxy group selected from – OCH₂NH₂, –OCH₂NHMe, –OCH₂NMe₂, –OCH₂NHEt, –OCH₂NEt₂, –OCH₂CH₂NH₂, –OCH₂CH₂NHMe, –OCH₂CH₂NMe₂, –OCH₂CH₂NHEt, and –OCH₂CH₂NEt₂;
- a sulphonyl group selected from –SO₂Me, –SO₂Et, –SO₂Pr, –SO₂iPr, –SO₂Ph, –SO₂-(2,3 or 4)-F-Ph, –SO₂-cyclopropyl, –SO₂CH₂CH₂OCH₃;
- a sulphonylamino group selected from –SO₂NH₂, –SO₂NHMe, –SO₂NMe₂, –SO₂NHEt, –SO₂NEt₂, –SO₂-pyrrolidine-N-yl, –SO₂-morpholine-N-yl, –SO₂NHCH₂OMe, and –SO₂NHCH₂CH₂OMe;
- an aminosulphonyl group selected from –NHSO₂Me, –NHSO₂Et, –NHSO₂Pr, –NHSO₂iPr, –NHSO₂Ph, –NHSO₂-(2,3 or 4)-F-Ph, –NHSO₂-cyclopropyl, –NHSO₂CH₂CH₂OCH₃;
- a cyclic aminosulphonyl- group selected from –N(SO₂)(CH₂)₃ and –N(SO₂)(CH₂)₄;
- a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1-yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl;

wherein each of R⁷¹, R⁷², and R⁷⁵ is independently H or a group selected from the following groups:

- a halogen selected from F, Cl, Br and I;
- a linear or branched C₁-C₆ alkyl group selected from methyl (Me), ethyl (Et), propyl (Pr), iso-propyl (i-Pr), n-butyl (n-Bu), iso-butyl (i-Bu), tert-butyl (t-Bu), pentyl and hexyl;

- a linear or branched C₁-C₆ alkyl-aryl group selected from -CH₂Ph, -CH₂(2,3 or 4)F-Ph, -CH₂(2,3 or 4)Cl-Ph, -CH₂(2,3 or 4)Br-Ph, -CH₂(2,3 or 4)I-Ph, -CH₂CH₂Ph, -CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂Ph, -CH₂CH₂CH₂CH₂CH₂Ph, and -CH₂CH₂CH₂CH₂CH₂CH₂Ph;
- a linear or branched C₁-C₆ halogenated alkyl group selected from -CH₂F, -CH₂Cl, -CH₂Br, -CH₂I, -CF₃, -CCl₃, -CBr₃, -CI₃, -CH₂CF₃, -CH₂CCl₃, -CH₂CB_{r3}, and -CH₂CI₃;
- a linear or branched primary, secondary or tertiary C₁-C₆ amine group selected from -NH₂, -NMeH, -NMe₂, -NEtH, -NEtMe, -NEt₂, -NPrH, -NPrMe, -NPrEt, -NPr₂, -NBuH, -NBuMe, -NBuEt, -CH₂-NH₂, -CH₂-NMeH, -CH₂-NMe₂, -CH₂-NEtH, -CH₂-NEtMe, -CH₂-NEt₂, -CH₂-NPrH, -CH₂-NPrMe, and -CH₂-NPrEt;
- an amino-aryl group selected from -NH-Ph, -NH-(2,3 or 4)F-Ph, -NH-(2,3 or 4)Cl-Ph, -NH-(2,3 or 4)Br-Ph, -NH-(2,3 or 4)I-Ph, -NH-(2,3 or 4)Me-Ph, -NH-(2,3 or 4)Et-Ph, -NH-(2,3 or 4)Pr-Ph, -NH-(2,3 or 4)Bu-Ph, -NH-(2,3 or 4)OMe-Ph, -NH-(2,3 or 4)OEt-Ph, -NH-(2,3 or 4)OPr-Ph, -NH-(2,3 or 4)OBu-Ph, -NH-2,(3,4,5 or 6)F₂-Ph, -NH-2,(3,4,5 or 6)Cl₂-Ph, -NH-2,(3,4,5 or 6)Br₂-Ph, -NH-2,(3,4,5 or 6)I₂-Ph, -NH-2,(3,4,5 or 6)Me₂-Ph, -NH-2,(3,4,5 or 6)Et₂-Ph, -NH-2,(3,4,5 or 6)Pr₂-Ph, -NH-2,(3,4,5 or 6)Bu₂-Ph;
- a cyclic amino or amido group selected from pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, 2-keto-pyrrolidinyl, 3-keto-pyrrolidinyl, 2-keto-piperidinyl, 3-keto-piperidinyl, and 4-keto-piperidinyl;
- a cyclic C₃-C₈ alkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
- a linear or branched C₁-C₆ alcohol group selected from -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂OH, -CH₂CH₂CH₂CH₂CH₂OH, and -CH₂CH₂CH₂CH₂CH₂CH₂OH;

- a linear or branched acyl group selected from $-(\text{CO})\text{Me}$, $-(\text{CO})\text{Et}$, $-(\text{CO})\text{Pr}$, $-(\text{CO})\text{iPr}$, $-(\text{CO})\text{nBu}$, $-(\text{CO})\text{iBu}$, $-(\text{CO})\text{tBu}$, $-(\text{CO})\text{Ph}$, $-(\text{CO})\text{CH}_2\text{Ph}$, $-(\text{CO})\text{CH}_2\text{OH}$, $-(\text{CO})\text{CH}_2\text{OCH}_3$, $-(\text{CO})\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{CH}_2\text{NHMe}$, $-(\text{CO})\text{CH}_2\text{NMe}_2$, $-(\text{CO})\text{-cyclopropyl}$, $-(\text{CO})\text{-1,3-epoxypropan-2-yl}$; $-(\text{CO})\text{NH}_2$, $-(\text{CO})\text{NHMe}$, $-(\text{CO})\text{NMe}_2$, $-(\text{CO})\text{NHEt}$, $-(\text{CO})\text{NEt}_2$, $-(\text{CO})\text{-pyrrolidine-N-yl}$, $-(\text{CO})\text{-morpholine-N-yl}$, $-(\text{CO})\text{-piperazine-N-yl}$, $-(\text{CO})\text{-N-methyl-piperazine-N-yl}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OH}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{OMe}$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NH}_2$, $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NHMe}$, and $-(\text{CO})\text{NHCH}_2\text{CH}_2\text{NMe}_2$;

- a linear or branched $\text{C}_1\text{-C}_6$ carboxylic acid ester group selected from $-\text{COOMe}$, $-\text{COOEt}$, $-\text{COOPr}$, $-\text{COO-i-Pr}$, $-\text{COO-n-Bu}$, $-\text{COO-i-Bu}$, $-\text{COO-t-Bu}$, $-\text{CH}_2\text{COOMe}$, $-\text{CH}_2\text{CH}_2\text{COOMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{COOMe}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{COOMe}$;

- a linear or branched $\text{C}_1\text{-C}_6$ amide group selected from $-\text{CO-NH}_2$, $-\text{CO-NMeH}$, $-\text{CO-NMe}_2$, $-\text{CO-NEtH}$, $-\text{CO-NEtMe}$, $-\text{CO-NEt}_2$, $-\text{CO-NPrH}$, $-\text{CO-NPrMe}$, and $-\text{CO-NPrEt}$;


- a linear or branched $\text{C}_1\text{-C}_7$ amino acyl group selected from $-\text{NH-CO-Me}$, $-\text{NH-CO-Et}$, $-\text{NH-CO-Pr}$, $-\text{NH-CO-Bu}$, $-\text{NH-CO-pentyl}$, $-\text{NH-CO-hexyl}$, $-\text{NH-CO-Ph}$, $-\text{NMe-CO-Me}$, $-\text{NMe-CO-Et}$, $-\text{NMe-CO-Pr}$, $-\text{NMe-CO-Bu}$, $-\text{NMe-CO-pentyl}$, $-\text{NMe-CO-hexyl}$, $-\text{NMe-CO-Ph}$;

- a linear or branched $\text{C}_1\text{-C}_7$ alkoxy or aryloxy group selected from $-\text{OMe}$, $-\text{OEt}$, $-\text{OPr}$, $-\text{O-i-Pr}$, $-\text{O-n-Bu}$, $-\text{O-i-Bu}$, $-\text{O-t-Bu}$, $-\text{O-pentyl}$, $-\text{O-hexyl}$, $-\text{OCH}_2\text{F}$, $-\text{OCHF}_2$, $-\text{OCF}_3$, $-\text{OCH}_2\text{Cl}$, $-\text{OCHCl}_2$, $-\text{OCCl}_3$, $-\text{O-Ph}$, $-\text{O-CH}_2\text{-Ph}$, $-\text{O-CH}_2\text{-(2,3 or 4)-F-Ph}$, $-\text{O-CH}_2\text{-(2,3 or 4)-Cl-Ph}$, $-\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{OEt}$, $-\text{CH}_2\text{OPr}$, $-\text{CH}_2\text{OBu}$, $-\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$, and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OMe}$;


- a linear or branched aminoalkoxy group selected from $-\text{OCH}_2\text{NH}_2$, $-\text{OCH}_2\text{NHMe}$, $-\text{OCH}_2\text{NMe}_2$, $-\text{OCH}_2\text{NHEt}$, $-\text{OCH}_2\text{NEt}_2$, $-\text{OCH}_2\text{CH}_2\text{NH}_2$, $-\text{OCH}_2\text{CH}_2\text{NHMe}$, $-\text{OCH}_2\text{CH}_2\text{NMe}_2$, $-\text{OCH}_2\text{CH}_2\text{NHEt}$, and $-\text{OCH}_2\text{CH}_2\text{NEt}_2$;

- a sulphonyl group selected from -SO₂Me, -SO₂Et, -SO₂Pr, -SO₂iPr, -SO₂Ph, -SO₂-(2,3 or 4)-F-Ph, -SO₂-cyclopropyl, -SO₂CH₂CH₂OCH₃;
 - a sulphonylamino group selected from -SO₂NH₂, -SO₂NHMe, -SO₂NMe₂, -SO₂NHEt, -SO₂NEt₂, -SO₂-pyrrolidine-N-yl, -SO₂-morpholine-N-yl, -SO₂NHCH₂OMe, and -SO₂NHCH₂CH₂OMe;
 - an aminosulphonyl group selected from -NHSO₂Me, -NHSO₂Et, -NHSO₂Pr, -NHSO₂iPr, -NHSO₂Ph, -NHSO₂-(2,3 or 4)-F-Ph, -NHSO₂-cyclopropyl, -NHSO₂CH₂CH₂OCH₃;
 - a cyclic aminosulphonyl- group selected from -N(SO₂)(CH₂)₃ and -N(SO₂)(CH₂)₄;
 - a saturated or unsaturated heterocyclic group selected from pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiphen-1-yl, thiphen-2-yl, thiphen-3-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, tetrazole-1-yl, tetrazole-2-yl, tetrazole-3-yl, tetrazole-4-yl, tetrazole-5-yl, (1,3,4-oxadiazol)-1-yl, (1,3,4-oxadiazol)-2-yl, (1,3,4-oxadiazol)-3-yl, (1,3,4-oxadiazol)-4-yl, (1,3,4-oxadiazol)-5-yl, (1,2,4-oxadiazol)-1-yl, (1,2,4-oxadiazol)-2-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-4-yl, (1,2,4-oxadiazol)-5-yl, (1,3-thiazol)-1-yl, (1,3-thiazol)-2-yl, (1,3-thiazol)-3-yl, (1,3-thiazol)-4-yl, (1,3-thiazol)-5-yl, furan-1-yl, furan-2-yl, and furan-3-yl;
- or wherein two of R⁷¹ and/or two of R⁷² when attached to the same carbon atom may together form a ketone group.


17. A compound, wherein the compound is selected from the group consisting of:




72




74




76




78




79




80




81




82




83




84




85




86




87




88




90




91




92




93




94




95




96




98




99




100




101




102




104




105




106




107




108




109




110




111




112




114




115









116





117




118









148




149




150




151




152




153




154




155




156




157







170




171




172




173




174




175




176




177




178




179




180




181




182




183




184




185




189




190




191




192




193




194




195




196




197




199




200




201




202




203




204




205




206




207




210




211




212




213




214




215




218




219




220




221




222




223




225




226




227




229




230




231




232




233




234




235




236




237




238




239




240




241




242




243




244




245




246




247




248







264




266




270




275




277




278




279




280




281




282




283




284




285




286




287




289




290




291




292




293




294




295




298




299




300




301




303




304




305




307




308




309




310




312




313




314




315




316




317




318




319




320




324




325




326




327




328




329




332




333




334



335




336




337







352




353




354




355




356




357




359




360




361




362




363




364




365




367




368




369




370




371




372




373




374




375




376




377



378



379



18. A compound according to any one of claims 1 to 10 and 15 to 17 for use in therapy.

19. Use of a compound according to any one of claims 1 to 10 and 15 to 17 in the manufacture of a medicament for the treatment of cancer, an inflammatory condition, an autoimmune condition, a neurological condition, a proliferative disorder and/or a metabolic condition.